-
MGX292 Announced as PAH Therapy Candidate
Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension. Click here to read more.
What do you think about this news?
Sorry, there were no replies found.
Log in to reply.